WEZLANA
Google image searchProduct monograph
Active ingredient
ustekinumab, 45 MG/0.5 ML
DIN: 02544202
Dosage form(s): SOLUTION
Route(s) of administration: SUBCUTANEOUS
Description: SINGLE-USE VIAL
Schedule: Prescription / Schedule D
Company: AMGEN CANADA INC
Date: 01-MAR-2024
ATC:
- L04 — IMMUNOSUPPRESSANTS (ATC, ATC/DDD, )
- L04A — IMMUNOSUPPRESSANTS (ATC, ATC/DDD)
- L04AC — Interleukin inhibitors (ATC, ATC/DDD)
- L04AC05 — USTEKINUMAB (ATC/DDD)
Reference brand drug: Stelara
